NEW YORK, May 18, 2026, 09:07 EDT
- QNCX was last quoted at $1.15 before the regular Nasdaq open, with the latest available trade timestamped 8:50 a.m. EDT.
- Nantahala Capital Management amended a passive ownership filing, reporting beneficial ownership of 4.53 million shares, or 7.52% of the class.
- The company’s latest quarterly filing says Quince has no current product candidates and flagged substantial doubt about its ability to continue as a going concern.
Quince Therapeutics Inc. shares headed into Monday’s session under fresh scrutiny after a late-Friday ownership filing added another data point to a stock already being driven less by drug-development news than by restructuring, Nasdaq compliance and cash runway.
The regular Nasdaq session had not yet opened in New York. Nasdaq’s posted hours are 9:30 a.m. to 4 p.m. Eastern Time, with premarket trading running from 4 a.m. to 9:30 a.m.; the exchange also warns that extended-hours trading can have less liquidity, meaning fewer buyers and sellers, and sharper price swings.
The timing matters because Quince is no longer a normal late-stage biotech story. Its May 11 10-Q said the company had $18.2 million in cash and cash equivalents at March 31, had no current product candidates, and was preserving cash while weighing strategic alternatives. “Going concern” is the accounting phrase companies use when there is doubt they can keep operating for at least a year without more funding. Quince Therapeutics
Nantahala’s amended Schedule 13G/A, a filing used by certain investors to report passive stakes, said Nantahala Capital Management, Wilmot B. Harkey and Daniel Mack may be deemed beneficial owners of 4,528,302 shares as of March 31. The figure includes shares that could be acquired within 60 days through convertible securities, the filing showed.
Quince is also asking shareholders at its June 11 annual meeting to approve another reverse stock split, this time in a range of 1-for-10 to 1-for-100. A reverse stock split cuts the number of shares while lifting the nominal price per share; it does not by itself change a holder’s percentage ownership. The company said it had already completed a 1-for-10 split effective on Nasdaq on April 13 after falling below the exchange’s minimum bid-price rule.
The larger overhang is Nasdaq listing status. Quince said in its quarterly filing it had regained compliance with the $1 minimum bid rule, but had not yet regained compliance with Nasdaq’s $50 million minimum market value of listed securities requirement, with an initial deadline of Sept. 14. Market value of listed securities is one Nasdaq test of whether a company is large enough to keep its listing.
The stock’s collapse earlier this year followed Quince’s failed Phase 3 NEAT trial of eDSP in ataxia-telangiectasia, a rare inherited neurodegenerative and immune disorder. Statistical significance means a trial result is unlikely to be due to chance; Quince said the study’s primary and key secondary endpoints did not reach that bar, and it stopped clinical development of eDSP.
Chief Executive and Chief Medical Officer Dirk Thye said in March that settling European Investment Bank debt was a “meaningful step forward” for Quince as it worked to restructure and evaluate alternatives. The company said that $5.5 million payment resolved about $16.4 million of obligations. Quince Therapeutics
Competitive context is awkward for Quince. Privately held IntraBio said in January its Phase 3 levacetylleucine trial in ataxia-telangiectasia met its primary and key secondary endpoints, and that it planned regulatory submissions in the United States and Europe. Quince’s own program failed days later, leaving the stock more exposed to balance-sheet and deal-process headlines than to pipeline progress.
The broader biotech tape was also soft before the bell, with early data showing the SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF lower. An exchange-traded fund, or ETF, is a basket of securities that trades like a stock and is often used as a quick read on sector sentiment.
But the risk case remains plain. Quince has said it has no signed strategic transaction, may not secure funding on favorable terms or at all, and could face material consequences if Nasdaq delists the stock, including reduced liquidity and a weaker position for any reverse merger.
